CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 308 · Search date 2026-07-11 · Methodology v0.6

Lactobacillus-fermented kelp extract,
does it really help with Liver function and liver-marker improvement?

30-Second Summary
C
Evidence Grade C · 48 · Safety caution
A specific fermented kelp ingredient has a short-term liver-enzyme signal but no independent evidence for clinical outcomes
What the
research shows
In a 48-person RCT, 1.5 g/day of a specific kelp extract fermented with Lactobacillus brevis BJ20 for four weeks lowered GGT, AST, and ALT relative to placebo. However, the study assessed only enzyme and oxidative-stress surrogate markers in men without clinical liver disease, and the published positive human evidence is concentrated in one trial involving authors from the ingredient developer; the rating is therefore C.
What the
ads claim
Product descriptions combine claims such as 'protection from alcohol-related injury,' 'improved liver function,' and 'antioxidant support.' The direct scope of the public human evidence is four-week measurement of blood liver enzymes and oxidative-stress markers in men with elevated GGT.
*

Useful facts when choosing a product

  • The human-trial ingredient was a specific kelp extract fermented with Lactobacillus brevis BJ20.
  • The published RCT dose was 1.5 g/day for four weeks.
  • The main outcomes were GGT, AST, ALT, and oxidative-stress markers; liver imaging, histology, and liver-related events were not measured.
  • Kelp-derived products can differ in iodine content and manufacturing process, so ordinary kelp products cannot be equated with the study ingredient.
Gap Measurement · Verdict 308 · C 48
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

A four-week trial assigned 48 otherwise healthy men with elevated GGT to fermented kelp extract at 1.5 g/day or placebo. GGT was lower with the fermented extract than with placebo, and AST, ALT, 8-isoprostane, 8-OHdG, and protein carbonyl also improved. The 2012 and 2014 papers report the same 48 participants at the same dose and duration and therefore do not count as two independent replications. The earlier published work was in rats. No independent repeat human trial of the same ingredient or study of liver imaging, histology, or clinical events was identified.

02

Why this is classified as C (48)

Regulatory recognition itself is not grading evidence. Several liver enzymes improved directionally in a randomized placebo-controlled human trial, but the evidence consists of 48 participants, four weeks, surrogate endpoints, ingredient-developer authors, and one manufacturer-specific product. The 2012 and 2014 papers use the same 48-person dataset and are not independent replications; the absence of independent replication supports C with 48 points.

Counterpoint. A short-term signal for improvement in GGT, AST, and ALT remains when the tested ingredient and dose match. This judgment does not include improvement of clinical liver disease or effects of ordinary kelp.

Rejudgment record. Reassessment (cross-check reflected) — Regulatory recognition is not grading evidence; a four-week trial in 48 men with elevated GGT was positive, but the endpoints were liver-enzyme and oxidative-stress surrogates, company authors were involved, and the 2012 and 2014 papers use the same dataset rather than independent replications

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kang YM et al. 2014Randomized double-blind placebo-controlled trial48Included authors affiliated with the ingredient developer; external funding unknownGGT, AST, ALT, LDH, 8-isoprostane, 8-OHdG, and protein carbonylFour weeks of fermented kelp extract at 1.5 g/day produced lower GGT than placebo and also improved AST, ALT, and oxidative-stress markers.Key, manufacturer-linked
Lee BJ et al. 2010Animal study of ethanol- and carbon-tetrachloride-induced liver injuryIncluded authors affiliated with the ingredient developerGPT, GGT, MDA, and hepatic antioxidant enzymesFermented kelp reduced serum liver enzymes and oxidative injury, but this was not a human outcome.Preclinical support
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-11).

Kang YM, Lee BJ, Kim JI, Nam BH, Cha JY, Kim YM, Choi JS, Choi IS, Je JY. Fermented Sea Tangle Attenuates Oxidative Stress in Individuals with a High Level of γ-Glutamyltransferase: a Randomized, Double-Blind, and Placebo-controlled Clinical Study. Food Sci Biotechnol. 2014;23(3):937-941. DOI: 10.1007/s10068-014-0126-0.
checked
Lee BJ, Senevirathne M, Kim JS, et al. Protective effect of fermented sea tangle against ethanol and carbon tetrachloride-induced hepatic damage in Sprague-Dawley rats. Food Chem Toxicol. 2010;48(4):1123-1128. PMID: 20138953. DOI: 10.1016/j.fct.2010.02.006.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Lactobacillus-fermented kelp extract × liver function and liver-marker improvement Evidence Grade C card
[Chamgap] Lactobacillus-fermented kelp extract × liver function and liver-marker improvement — Evidence Grade C·48. 2 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/liver/lactobacillus-fermented-kelp-liver-markers/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.